Compare Adaptive Biotechnologies Corp (ADPT) vs Dell Technologies Inc (DELL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Dell Technologies Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.09 (market cap $3.33B), while Dell Technologies Inc trades at $430.96 (market cap $269.62B). The key difference: Dell Technologies Inc is far larger — about 81× Adaptive Biotechnologies Corp's market cap, and Dell Technologies Inc pays a 0.6% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | DELL | |
|---|---|---|
Market Cap | $3.33B | $269.62B |
Sector | Health | Technology |
52-Week High | $22.37 | $466.02 |
52-Week Low | $10.24 | $111.10 |
Enterprise Value | $3.19B | $289.21B |
Dividend Yield | — | 0.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Dell Technologies trades at $416.98, up 5.75% in the last 24 hours, with a bullish technical signal from moving averages and a consensus analyst price target of $484.28. Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $4.86 surpassing the $2.96 estimate. The company shows strong revenue growth projections to $134 billion in 2026 and benefits from AI server demand, though net cash flow was negative $3.69 billion in 2025.
The outlook for Dell is positive, driven by AI infrastructure dominance and expanding profit margins, but risks include supply constraints, competitive pressures, and negative shareholder equity. With 57.8% of analysts rating it a buy, the stock offers growth potential, yet investors should weigh execution risks against the robust AI-driven revenue backlog.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Dell Technologies Inc
VMware is an industry titan in virtualizing IT infrastructure and became a stand-alone entity after spinning off from Dell Technologies in November 2021. The software provider operates in the three segments: licenses
Read more on DELL →
